explore -WSS

explore

author：fashion 2025-08-23 08:54:33 - browse：53399

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： WHO may add ‘noma' to its list of neglected tropical diseases

hotspot

WSS

Why Sanofi got shellacked over its spinoff

Readout Newsletter: New research from Sanofi, Regeneron, etc.

First Opinion Podcast: How to protect health care in times of war

Disclosing genetic information: not as worrisome as once feared

Testing for cancer recurrence creates a new limbo for patients

Do masks work? RCTs can't tell us

hotspot

explore

focus

23andMe had bad news about my health. I wish a person had delivered it

Why we need to separate burnout from moral injury in health care

Medicare details structure of new drug price negotiation program

CDC recommends rationing of RSV shot due to shortages

Anesthesiologist group: stop taking Ozempic before surgery

Weight bias in eating disorder treatment complicated by new weight loss drugs

The high cost of giving birth even with insurance

CDC concerned about possible undetected monkeypox spread in U.K.

Wildfire smoke exposes gaps in outdoor worker protections

First Opinion Podcast: How to protect health care in times of war

focus

Diversifying clinical trials isn't enough to close racial gaps: study

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Eli Lilly to pay $200M for Beam’s stake in gene

WATCH: Why do fingernails fall off when they're damaged?

The science behind Janet Jackson's pregnancy at 49

The battle over the Brookhaven Landfill on Long Island

hotspot

hotspot

focus

hotspot